A Placebo Controlled, Double-blind, Randomized, Parallel-group, Multi-center Phase III Study to Determine the Efficacy and Safety of TissueGene-C in Patients With Degenerative Arthritis

Trial Profile

A Placebo Controlled, Double-blind, Randomized, Parallel-group, Multi-center Phase III Study to Determine the Efficacy and Safety of TissueGene-C in Patients With Degenerative Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Tonogenchoncel-L (Primary)
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Kolon Life Science
  • Most Recent Events

    • 13 Jul 2017 According to a BioLife Solutions media release, Kolon Life Science has received marketing approval for tonogenchoncel-L (Invossa-K Inj.) for degenerative arthritis from the Korea Ministry of Food and Drug Safety (MFDS). The approval was based on results of this trial.
    • 01 Nov 2016 According to a TissueGene media company has filed a biologics license application with the Korea Ministry of Food and Drug Safety (MFDS).
    • 01 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top